Dr. John Hornberger is a health services and policy researcher focused on comprehensive assessments – i.e., clinical outcomes, costs, and cost-effectiveness – of emerging pharmaceutical, diagnostics, and device technologies in cancer, infectious diseases (HIV, hepatitis, and herpes zoster), renal disease, eye and skin disease, and others. In cancer, he published a seminal paper evaluating one of the first, licensed genomic assays to predict recurrence risk among women with early-stage breast cancer. Other assessments that he has conducted include: rituximab for treatment of diffuse large B-cell lymphoma in older adults, capecitabine for anthracycline-pretreated patients with advanced breast cancer, cervical vaginal smear interpretation of atypical squamous cells of undetermined significance (ASCUS), and testing strategies in the diagnosis of lung and breast cancer. His work is cited in international appraisals of new cancer technologies, such as the UK National Institute of Clinical Excellence and the Canadian Coordinating Office for Health Technology Assessment. He has been involved in facilitating first-ever development of clinical guidelines for such conditions as adequacy of renal dialysis and management of hyperhidrosis. He is currently working on a project with colleagues at The Johns Hopkins University concerning how to address the socioeconomic hurdles that prevent widespread adoption of anti-retroviral medications for persons living with HIV in severely resource-constrained parts of the world.
Dr. Hornberger also is an Adjunct Clinical Professor of Medicine at Stanford University School of Medicine, and is supervisory attending in a weekly clinic supervising and teaching resident housestaff and post-doctoral fellows in general internal medicine clinic. He received his M.D. degree from the University of Rochester, New York and M.S. degree in Health Services Research from Stanford University. He has papers published in Annals of Internal Medicine, American Journal of Public Health, Statistics in Medicine, Cancer, Controlled Clinical Trials, JAIDS, Medical Care, Management Science, American Heart Journal, Journal of the American Society of Nephrology, and Medical Decision Making. He is Co-Editor of Value in Health, is on the Editorial Board of Medical Decision Making, and has served on various NIH scientific and economic advisory committees.
